Answers are grounded in this paper and cite their sources.
The five-year survival rate of esophageal adenocarcinoma is poor (<20%) but a prior diagnosis of Barrett’s esophagus (BE) permits earlier detection of dysplasia or cancer when curative endoscopic treatment is still possible. The capsule-sponge-trefoil-factor-3 (TFF3) test is a minimally invasive, non-endoscopic test for BE. TFF3 is a biomarker for intestinal metaplasia and atypia is indicative of dysplasia.1,2 While studies have demonstrated good diagnostic accuracy, the positive predictive value (PPV) in active case-finding populations remains uncertain due to the limited number of patients with both a capsule-sponge-TFF3 test result and endoscopic follow-up. We performed the first pooled analysis across seven studies in active case-finding populations to provide precise, implementation-relevant estimates of test performance.
No takes yet. Share an insight, caveat, or question.
Somerset et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: